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c4c vision
c4c will use a coordinated approach to deliver high quality 
“regulatory grade” pediatric clinical trials in:
• Multiple countries (development Belgian national network)
• Multiple sites
• All pediatric age groups
• 10 EFPIA 
companies
• 18 pediatric 
national 
networks
• 2 large patient 
advocacy 
groups




• 2 large 
children’s 
hospitals
The c4c consortium members
Start-up Belgian pediatric clinical research network 
(in the context of c4c)(2018-2024)
Viability of the national networks 
will be tested with:
- Non-industry sponsored studies
- Industry sponsored studies
Non-industry sponsored studies (2019-2023)
- 57 letters of interest submitted to c4c (multidisciplinary)
- Feasibility of different studies was send to subdisciplines VUB
- 4 of the 57 studies will be selected 
- Belgium will take part in at least one study
Industry sponsored studies (2019-2023)
- Feasibility will be send by the c4c (requested by industry)
- At the moment: 1 survey J&J (IBD, feasibility completed) 
- 4 studies will be selected
- Belgium will take part in at least one study via the national hub
Viability c4c network
Implementation Belgian pediatric clinical research 
network (2024-)
The Telemonitoring and ACE 








• ACE-inhibitors are the prototype of the FDA and EU-
regulations on pediatric drug CT
• Adult blockbusters.. With adult incentive
• PIP mandatory 
• Previous regulatory trials largely excluded the pediatric 
populations in greatest need of antihypertensive drugs, i.e. 
patients with advanced CKD and/or severe hypertension , 
comorbidities 
• failed to receive drug approval.. 
• Pediatric blood pressure (BP) management faces various 
practical challenges, which include infrequent doctor 
visits of otherwise healthy children, common white-coat 
HTN, and poor adherence of adolescents. 
Arterial hypertension 
(HTN) + ACE-i
• A previous trial (Wühl, NEJM 2009) demonstrated a 
substantial nephroprotective benefit of intensified BP 
control using ACE inhibition, which lead to international 
recommendations for BP targets in the low-normal 
range for children with CKD (Lurbe, J Hypertens 2016). 
• However, a recent ‘real-world’ study revealed that 
current BP management fails to achie
• ve recommended targets in a large proportion of 
European children (Schaefer, cJASN 2017). The recent 
ESH pediatric HTN guideline lists personalized 
antihypertensive dosing and innovative BP monitoring 
technologies as research priorities. 
c4c offers a unique opportunity 
to perform a practice-changing 
clinical trial by 
• (1) using the transnational network combining general pediatric and 
pediatric nephrology expertise to assemble a large cohort of children 
with essential and renal HTN, 
• (2) exploiting the unique pediatric clinical pharmacology expertise 
available in the network, and 
• (3) involving patients and families in designing a trial meeting their 
needs both in terms of study feasibility and facilitation of day-to-day BP 
management. 
• While BP telemonitoring was demonstrated to facilitate BP control in 
hypertensive adults (Franssen, Lancet 2018), the feasibility and efficacy 
of this innovative technology awaits exploration in children. 
• Furthermore, we hypothesize that the efficacy and safety of ACE 
inhibition can be optimized by rational utilization of pharmacokinetic 
(PK) and endocrine biomarker information.
Aim of the trial
• The planned trial will 
• develop and demonstrate efficacious use of the emerging 
pan-European network infrastructure along with expert and 
young patient advisory support during trial planning and 
execution; 
• to test the potential of PK data, renin/angiotensin blood 
levels and other biochemical markers to predict the 
antihypertensive and antiproteinuric efficacy and safety of 
the ACE inhibitor lisinopril, aiming to develop an 
individualized dosing concept to avoid both overtreatment 
and treatment resistance
Methods :
• Hypertensive patients aged 2-17 years will be started on lisinopril
monotherapy dosed according to GFR
• PK profiles and plasma renin/aldosterone will be measured after 
treatment start. 
• Patients will be stratified by age, GFR and HTN type and 
randomized to standard-of-care management or BP 
telemonitoring. 
• While all families will receive telemetric BP monitors and central 
surveillance to maximize treatment safety, 
• only In the intervention arm telemonitoring access will be 
provided also to local investigators, enabling them to frequently 
adapt medications to achieve the BP target 
C4C: national coordinator : 
Régis Hancard
• Olivia Boyer-Gillion France Paris,Hopital Necker
Enfants Malades Study site
• Justine Bacchetta France Lyon, UCH Study site
• Robert Novo France Lille, UCH Study site
• Ariane Zalozyc France Strasbourg, UCH de 
Hautepierre Study site
• Jerome Harambat France Bordeaux, UCH Study site
• Others ?  Johan.Vandewalle@uzgent.be
